Maia Biotechnology Stock Total Debt
| MAIA Stock | USD 2.09 0.01 0.48% |
MAIA Biotechnology fundamentals help investors to digest information that contributes to MAIA Biotechnology's financial success or failures. It also enables traders to predict the movement of MAIA Stock. The fundamental analysis module provides a way to measure MAIA Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MAIA Biotechnology stock.
The current year's Total Debt To Capitalization is expected to grow to -0.15. MAIA | Total Debt |
MAIA Biotechnology Company Total Debt Analysis
MAIA Biotechnology's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current MAIA Biotechnology Total Debt | 7.09 M |
Most of MAIA Biotechnology's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MAIA Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
MAIA Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for MAIA Biotechnology is extremely important. It helps to project a fair market value of MAIA Stock properly, considering its historical fundamentals such as Total Debt. Since MAIA Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of MAIA Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of MAIA Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
MAIA Total Debt Historical Pattern
Today, most investors in MAIA Biotechnology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various MAIA Biotechnology's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of MAIA Biotechnology total debt as a starting point in their analysis.
MAIA Biotechnology Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
MAIA Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, MAIA Biotechnology has a Total Debt of 7.09 M. This is 99.74% lower than that of the Biotechnology sector and 97.82% lower than that of the Health Care industry. The total debt for all United States stocks is 99.87% higher than that of the company.
MAIA Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MAIA Biotechnology's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MAIA Biotechnology could also be used in its relative valuation, which is a method of valuing MAIA Biotechnology by comparing valuation metrics of similar companies.MAIA Biotechnology is currently under evaluation in total debt category among its peers.
MAIA Biotechnology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, MAIA Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to MAIA Biotechnology's managers, analysts, and investors.Environmental | Governance | Social |
MAIA Fundamentals
| Return On Equity | -5.6 | ||||
| Return On Asset | -1.07 | ||||
| Current Valuation | 44 M | ||||
| Shares Outstanding | 25.33 M | ||||
| Shares Owned By Insiders | 17.49 % | ||||
| Shares Owned By Institutions | 7.50 % | ||||
| Number Of Shares Shorted | 662.41 K | ||||
| Price To Book | 32.55 X | ||||
| EBITDA | (20.18 M) | ||||
| Net Income | (19.77 M) | ||||
| Cash And Equivalents | 8.15 M | ||||
| Cash Per Share | 0.75 X | ||||
| Total Debt | 7.09 M | ||||
| Current Ratio | 2.78 X | ||||
| Book Value Per Share | 0.03 X | ||||
| Cash Flow From Operations | (13.07 M) | ||||
| Short Ratio | 10.99 X | ||||
| Earnings Per Share | (1.34) X | ||||
| Target Price | 12.63 | ||||
| Number Of Employees | 13 | ||||
| Beta | 0.34 | ||||
| Market Capitalization | 52.69 M | ||||
| Total Asset | 7.57 M | ||||
| Retained Earnings | (63.98 M) | ||||
| Working Capital | 2.63 M | ||||
| Net Asset | 7.57 M |
About MAIA Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MAIA Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MAIA Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MAIA Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether MAIA Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of MAIA Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maia Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maia Biotechnology Stock:Check out MAIA Biotechnology Piotroski F Score and MAIA Biotechnology Altman Z Score analysis. For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MAIA Biotechnology. If investors know MAIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MAIA Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Return On Assets (1.07) | Return On Equity (5.60) |
The market value of MAIA Biotechnology is measured differently than its book value, which is the value of MAIA that is recorded on the company's balance sheet. Investors also form their own opinion of MAIA Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is MAIA Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MAIA Biotechnology's market value can be influenced by many factors that don't directly affect MAIA Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MAIA Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if MAIA Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MAIA Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.